

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12P 17/06	A1	(11) International Publication Number: WO 97/06273 (43) International Publication Date: 20 February 1997 (20.02.97)
(21) International Application Number: PCT/US96/12563 (22) International Filing Date: 7 August 1996 (07.08.96) (30) Priority Data: 08/512,192 7 August 1995 (07.08.95) US (71) Applicant: FERMALOGIC, INC. [US/US]; 2201 W. Campbell Park Drive, Chicago, IL 60612 (US). (72) Inventors: WEBER, J., Mark; 3100 N. Lake Shore Drive #2103, Chicago, IL 60657 (US). CONSTANTINOU, Andreas; 1516 E. Bailey, Naperville, IL 60565 (US). HESSLER, Paul, E.; 6815 W. 32nd Street, Berwyn, IL 60402 (US). (74) Agents: NORTHRUP, Thomas, E. et al.; Dressler, Goldsmith, Milnamow & Katz, Ltd., Suite 4700, 180 N. Stetson, Chicago, IL 60601 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: A PROCESS OF PREPARING GENISTEIN (57) Abstract The present invention provides a process of preparing the isoflavone genistein. Genistein is prepared by fermenting the bacteria <i>Saccharopolyspora erythraea</i> in the presence of a soy-based substrate. A process of recovering genistein from a bacterial fermentation medium using alkaline, organic solvent extraction is also provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

A PROCESS OF PREPARING GENISTEIN

Technical Field of the Invention

5 The field of this invention is genistein production. More particularly, the field of this invention is genistein production using fermentation of the bacteria *Saccharopolyspora erythraea* on a soy-based substrate.

Background Of The Invention

10 Genistein is an isoflavone. Isoflavones are a subclass of flavonoids, natural products typically isolated in glycosylated form from plants. The aglycone is the biologically active form that has the most medical and commercial interest.

15 The glycosylated form of genistein is known as genistin. The preparation of genistein must include a step in which the core isoflavone structure (genistein) is separated from the glucose moiety. Genistin, which is found in soybeans, is converted to the biologically active form, genistein, through the action of a beta-glucosidase enzyme.

20 Demand for genistein is expected to increase significantly in the near future. Genistein is becoming an established research tool as an inhibitor of protein tyrosine kinase, an enzyme involved in increased cell proliferation. Protein tyrosine kinase (PTK), is one of genistein's well studied biological targets. PTK is known to give cells a proliferative advantage. A variety of
25 oncogenes of the Src family have been shown to have tyrosine kinase activity. Genistein is a PTK inhibitor. Genistein inhibited the PTK activities of EGF-receptor and pp60v-src with an ID50 of 6 and 7 mg/ml respectively in experiments using purified components, but in intact A431 cells 40 mg/ml were required to inhibit the cellular phosphotyrosine levels. Genistein is reported to be
30 an inhibitor of eukaryotic DNA topoisomerase (topo) I and II.

35 Genistein is used as a chemopreventive agent in animal studies, is required for clinical trials as a dietary supplement; and likely has application as a chemotherapeutic agent when coupled to anti-tumor specific antibodies.

Populations consuming soybeans show reduced incidence of breast, colon, and prostate cancer. Initial animal studies suggested that two isoflavones, genistein and daidzein, may be the active ingredients of soybeans that function as chemopreventive agents. Genistein injected into neonatal rats reduces
5 dimethylbenz(a)anthracene (DMBA)-induced mammary tumor induction by about 50%. Either genistein or daidzein provides some protection against N-methyl N-nitrosurea (MNU)-induced mammary tumors in rats. Although genistein was effective in reducing both the tumor incidence and multiplicity, daidzein reduced only multiplicity in the later studies.

10 Currently genistein is being tested by the National Cancer Institute against colon carcinogenesis, as part of the Chemoprevention Screening Program, and early results show effectiveness against colon papillomas. Clinical trials to identify the metabolism and pharmacokinetics of genistein (phase I) are also being
15 currently performed.

A recent study identified genistein as a potent antitumor agent (when coupled with antitumor specific antibodies) against colon carcinogenesis of human B-cell leukemia in immunodeficient mice. The B43-genistein
20 immunoconjugate at less than one-tenth the maximum tolerated dose killed more than 99% of human leukemia cells. The postulated mechanism of genistein's action in this study was that of PTK inhibitor.

25 Because of the potential clinical use of genistein as a chemopreventive and/or chemotherapeutic agent it is becoming essential to produce this isoflavone and some of its promising structural analogs in larger quantities and to reduce its price. Genistein is currently expensive to produce using current technology. Chemically synthesized genistein or genistein extracted from soybeans currently can cost up to \$5,000 a gram. However, the compound is not produced routinely
30 in kilogram quantities at present.

The present invention provides an inexpensive process for the large scale production of genistein wherein *Saccharopolyspora erythraea*, the organism that is used in the commercial production of erythromycin, is fermented on a soy-based fermentation medium.
35

Brief Summary of The Invention

The present invention provides a process of preparing genistein comprising fermenting the bacteria *Saccharopolyspora erythraea* on a soy-based substrate. The genistein that is formed by this fermentation is then recovered from the fermentation medium. In accordance with this process, *Saccharopolyspora erythraea* is cultured for a period of time and under culture conditions sufficient for genistein formation. Suitable culture conditions include a temperature of from about 10°C to about 50°C in an aqueous, oxygenated medium having a pH value of from about 4.0 to about 9.0, which medium contains organic nutrients, vitamins and inorganic salts sufficient to maintain *Saccharopolyspora erythraea* viability. More preferably, the temperature is from about 20°C to about 30°C and the medium has a pH value of from about 6.0 to about 8.0. A preferred time of fermentation is from about 20 hours to about 250 hours.

Genistein is recovered from the fermentation or culture medium by extraction in a water-immiscible organic solvent at a pH value of from about 8.0 to about 11.0. Preferably, the pH value is from about 9.0 to about 10.0. A preferred organic solvent is ethyl acetate.

In another aspect, the present invention provides a process of recovering genistein from a bacterial fermentation medium comprising extracting genistein from the medium in a water-immiscible organic solvent at a pH value of from about 8.0 to about 11.0 and, preferably from about 9.0 to about 10.0. A preferred organic solvent is the same as set forth above. In a preferred embodiment, the bacterial fermentation is a fermentation of *Saccharopolyspora erythraea*.

Detailed Description of the Invention

I. The Invention

The present invention provides an inexpensive, large-scale process for preparing the isoflavone genistein. That process is based on the surprising discovery that genistein is produced during fermentation of the bacteria *Saccharopolyspora erythraea*, which is used in the commercial production of the antibiotic erythromycin. The present inventors have further discovered that

genistein is recovered from that fermentation along with erythromycin during alkaline, organic solvent extraction.

5 Typically, industrial fermentations are designed for the production of a single compound of interest such as an antibiotic. This compound is traditionally a biosynthetic product of the microorganism, referred to as a secondary metabolite. The growth medium is thought of strictly as a source of carbon and nitrogen and other necessary nutrients for the growth of the organism and production of the natural product from primary metabolic precursors produced by the microorganism.

10 The present disclosure that genistein is produced in the erythromycin fermentation enables one to recognize that the growth medium itself can be a significant source of additional products which can be used to add value to the overall fermentation.

15 The process of the present invention has advantages over other means for preparing genistein. When compared to chemical synthetic procedures, the present process is more efficient, less costly and capable of producing genistein in large-scale quantities. When compared to procedures involving the extraction of genistein from soy beans *per se*, the present process has the advantage of selectively producing genistein as opposed to its relatively inactive glycosylated precursor, genistin. This is true because *Saccharopolyspora erythraea* produces and secretes, during fermentation a unique form of a beta-glucosidase, which enzyme catalyses the removal of the glucose from genistin to form genistein.

20 This is highly advantageous not only because it is genistein, and not genistin, that is the biologically active compound but also because genistein (not genistin) is extractable from the fermentation medium broth under the same conditions (e.g., alkaline pH and organic solvent) that are used to recover erythromycin. It is surprising and unexpected that the same solvent and pH can be used to extract both genistein and erythromycin.

35 II. Process of Preparing Genistein

The present invention therefore provides a process of preparing genistein comprising fermenting *Saccharopolyspora erythraea* on a soy-based substrate.

As used herein, the term "fermenting" or its grammatical equivalents, refers to the process of culturing *Saccharopolyspora erythraea* in a medium that provides nutrients, vitamins and inorganic salts sufficient to maintain viability of the bacteria such that it will assimilate medium constituents (e.g., carbon and nitrogen) and produce erythromycin. Suitable media and conditions for bacterial fermentation are well known in the art. By way of example, United States Patent No. 2,653,899, the disclosure of which is incorporated herein by reference, discloses the fermentation of *Streptomyces erythreus* so as to produce erythromycin.

The fermentation of *Saccharopolyspora erythraea* to produce genistein in accordance with the present invention comprises culturing *Saccharopolyspora erythraea* for a period of time and under culture conditions sufficient for genistein formation. Culture conditions include, as is well known in the art, temperature and composition of the culture medium such as pH, nutrient levels, osmolality and the like.

As is also well known in the art, a preferred medium is an aqueous medium that is oxygenated. That medium contains assimilatable sources of carbon and nitrogen. Exemplary sources of carbon include, but are not limited to, carbohydrates such as starch, sugars (e.g., arabinose, fructose, galactose, maltose, sucrose) and organic salts (e.g., sodium acetate, sodium citrate, sodium malate). One of skill in the art can readily determine the optimum concentrations of such carbon sources in the culture medium.

The nitrogen source of the culture medium must include a soy-based substrate. As used herein, the term "soy-based substrate" refers to a substrate of any form that includes or is derived from soybeans. That soy-based substrate can be soybean meal, soybean flour, soybean oil, soybean grits, and the like. Such soy-based substrates are commercially available. Exemplary substrates and their commercial source are set forth hereinafter in the Examples.

The culture or fermentation medium can contain assimilatable nitrogen sources in addition to the soy-based substrate. Exemplary such additional nitrogen sources include, but are not limited to, corn steep, amino acid mixtures, casein, peptones and the like.

5 The culture medium further comprises inorganic salts that serve to provide any necessary cofactors for cell viability, genistein production and erythromycin production as well as for maintaining osmolarity within normal limits. Typically, as is well known in the art, those salts include sodium, potassium, chloride, magnesium calcium and the like. One of ordinary skill can readily determine the optimum levels of such inorganic salts. The pH of the culture medium is maintained at a suitable level for fermentation. A preferred medium pH value is from about 4.0 to about 9.0 and, more preferably from about 6.0 to about 8.0. Medium pH can be maintained with the use of buffers as needed.

10 As is well known in the art, fermentation can be performed over a wide range of temperatures. In a preferred embodiment, fermentation temperature is from about 10°C to about 45°C and, more preferably from about 20°C to about 40°C.

15 Fermentation is maintained for a period of time sufficient for genistein formation. That time will vary, as is well known in the art, on culture conditions, concentration of the bacteria and the like. Under culture conditions such as set forth above, suitable times typically range from about 20 hours to about 250 hours.

20 Genistein, formed from the fermentation of *Saccharopolyspora erythraea* in accordance with a process of the present invention is recovered from the fermentation or culture medium. Any means of recovering genistein can be used. It is preferred, however, to recover genistein using conditions similar to those used to recover erythromycin from the same medium. In accordance with this preferred embodiment and, as set forth below, genistein is recovered from the medium using organic solvent extraction at an alkaline pH.

30 III. Process of Recovering Genistein

In another aspect, therefore, the present invention provides a process of recovering genistein from a bacterial fermentation medium that contains genistein, the process comprising extracting the genistein from the fermentation medium in an organic solvent at a pH value of from about 8.0 to about 11.0.

5 In accordance with the process, the fermentation medium is adjusted to an alkaline pH by the addition of an alkalinizing salt. The alkaline pH can range from a pH value of about 8.0 to a pH value of about 11.0. More preferably, the pH value is from about a pH value of 9.0 to a pH value of about 10.0 and, even more preferably a pH value of about 9.5.

10 Any alkalinizing salt can be used so long as that salt does not interfere with the isolation and biological stability of genistein. An exemplary and preferred alkalinizing salt is sodium hydroxide.

15 The alkalinized fermentation medium is then extracted with an organic solvent. That organic solvent is preferably water immiscible. Any organic solvent can be used so long as that solvent does not interfere with the isolation or biological stability of genistein. Means for determining suitable such solvents are well known in the art and within the knowledge of one of ordinary skill in the art. Exemplary and preferred organic solvent include, but are not limited to alkyl esters of fatty acids (e.g., ethyl acetate, amyl acetate) chlorinated hydrocarbons (e.g., chloroform, ethylene dichloride), ethers, ketones and alcohols (e.g., butanol, amyl alcohol). Particularly preferred organic solvents are alcohols such as n-butanol and alkyl fatty acid esters such as amyl acetate and ethyl acetate.

20 Genistein is isolated and purified from the organic solvent extract (solvent fraction) using standard procedures well known in the art. By way of example, the solvent fraction is extracted with acidified water to remove the erythromycin: the genistein stays with the organic fraction and the erythromycin is extracted into the water fraction. Genistein is then isolated from the solvent using, typically, solvent evaporation and high pressure liquid chromatography (HPLC). A detailed description of the recovery of genistein using a process of the present invention is set forth hereinafter in the Example.

30 The following Example illustrates preferred embodiments of the present invention and is not limiting of the specification and claims in any way.

Example 1: Microbial Production Of Genistein

35 A variety of bacterial strains were studied for their ability to produce genistein. Three of those strains (Actinomycete bacteria) were reported to

produce isoflavones and were purchased from the American Type Culture Collection (ATCC). Those three strains were *Streptomyces roseolus* (ATCC 31047), and *Micromonospora halophytica* (subspecies *halophytica* and *nigra*) (ATCC 27596 and ATCC 33088). Control strains (not reported to produce isoflavones) studied were *Saccharopolyspora erythraea* (ATCC 11635), an erythromycin producer, *Streptomyces lividans* TK21 (Hopwood et al., 1985), an actinorhodin producer, *Streptomyces hygroscopicus* (ATCC 29253) an ascomycin producer, *Streptomyces glaucescens* NRLL, a tetracenomycin producer, and *E. coli* DH5alpha.

Various strains were grown (fermented) in eight different media as set forth below.

1. AVMM (disclosed in U.S. Patent No. 5,141,926, the disclosure of which is incorporated herein by reference) - asparagine (5 g), glucose (20 g), phosphate buffer at pH 7.0, essential vitamins (trace) and water (1 liter).
2. STB - Soytone Broth (Difco), yeast extract, NaCl (2.5 g), CaCO₃ (3.5 g), soluble starch (20 g) trace elements solution (0.25 ml) and water (1 liter).
3. SFB - SoyFluff Broth (Central Soya), yeast extract, NaCl (2.5 g), CaCO₃ (3.5 g), soluble starch (20 g) trace elements solution (0.25 ml) and water (1 liter).
4. SGB - NutraSoyaGrits (Cargill), yeast extract, NaCl (2.5 g), CaCO₃ (3.5 g), soluble starch (20 g) trace elements solution (0.25 ml) and water (1 liter).
5. G1 - NZ amine (20 g), yeast extract (10 g), soluble starch (20 g), NaCl (2.5 g), CaCO₃ (3.5 g), trace elements solution (1.0 ml), 50% glucose solution (20 ml) and water (980 ml).
6. SGGP - Bactopeptone (4 g), yeast extract (4 g), glycine (2 g), MgSO₄ (0.5 g), 0.5 M KH₂PO₄ (20ml), 50% glucose solution (20 ml) and water (960 ml).
7. SOD - tryptone (20 g), yeast extract (5 g), NaCl (0.5 g), 50% glucose solution (20 ml) and water (1 liter).
8. GM - beef extract (0.3%), tryptone (0.5%), dextrose (0.1%), soluble starch (2.4%) and water (1 liter).

Various bacterial strains were fermented in 50 ml of the various media at 30°C for 96 hours. 20 mls of each fermentation media were then extracted with

an equal volume of ethyl acetate. The solvent extract was evaporated to dryness, resuspended in about 100 microliters of ethyl acetate and subjected to HPLC. Extracts were examined for the presence of genistein and other isoflavones. The identification of genistein in the fermentation medium was made using standard
5 gas chromatography/mass spectroscopy (GC/MS) procedures well known in the art.

None of the bacterial strains produced isoflavones when fermented in media that did not contain a soy-based substrate (i.e., AVMM, G1, SGGP, SOD,
10 GM). These results were particularly surprising and unexpected with regard to those strains previously reported to produce isoflavones such as *Streptomyces roseolus* (ATCC 31047), and *Micromonospora halophytica* (subspecies *halophytica* and *nigra*)(ATCC 27596 and ATCC 33088). The present results bring into question the claims of U.S. Patent No. 3,973,608 to Umezawa et al.,
15 which discloses that *Streptomyces roseolus* produces isoflavone during fermentation. Although that patent disclosed soy-based fermentation media as a suitable medium, other non-soy-based media were disclosed as being suitable for isoflavone production.

In contrast, genistein was produced when *Streptomyces roseolus*, and *Micromonospora halophytica* were fermented in media (STB, SFB and SGB) containing a soy-based substrate. Surprisingly, however, the fermentation of *Saccharopolyspora erythraea*, a strain not previously reported to produce
20 isoflavones, also produced genistein in significant amounts when fermented in the presence of a soy-base substrate.
25

Extensive chemical analyses were performed on extracts from the *Streptomyces roseolus* and *Saccharopolyspora erythraea* fermentations. Briefly, purified material collected from HPLC was subjected to GC/MS analysis. The
30 results showed that the material corresponding to the peak eluting at 15 min. was genistein. These findings were based on a comparison between the mass spectrum of material isolated from the medium and an authentic genistein standard.

Identity of the material was also checked against apigenin. Apigenin is
35 the flavanone equivalent of genistein, having the same molecular weight and

substitution pattern. Its mass spectrum is identical to that of genistein, except that the two compounds were distinguishable by the significantly longer elution time of apigenin (23:12) as opposed to genistein's elution time (20:53). The two compounds could also be easily separated by HPLC.

5

Genistein was not present in the uninoculated broth containing soy-based substrates and was not produced by fermentation of any bacteria in media without a soy-based substrate. These findings, taken together, show that genistein is not produced *de novo* by the bacteria. This finding is in direct contradistinction to previous teachings about the bacterial production of genistein (See, e.g., U.S. Patent No. 3,973,608).

10

Although not wishing to be bound by a particular theory, it is believed that genistein is produced during fermentation through the beta-glucosidase catalyzed removal of glucose from genistin present in the soy-based substrate. The beta-glucosidase is likely produced by *Saccharopolyspora erythraea* and secreted into the fermentation medium where it acts on genistin. Beta-glucosidases are a family of substrate-specific enzymes that serve to catalyze the removal of sugar moieties from particular substrates (See, e.g., MacDonald et al., *Applied and Environmental Microbiology*, 47:350, 1984). Although beta-glucosidases have been reported to occur in over 400 microorganisms, there are no reports of any beta-glucosidase activity in *Saccharopolyspora erythraea* (See, e.g., Schliemann, *Pharmazie*, 38:1083, 1983). An examination of the report of Schliemann also reveals that there is no pattern to the particular type (i.e., substrate specificity) of beta-glucosidase amongst strains of bacteria. Thus, the observation that the fermentation of *Streptomyces griseus* on soybean meal resulted in genistein formation is, in no way, predictive of the present invention.

15

20

25

Saccharopolyspora erythraea produced 2.5 mg of genistein/ml of medium. The amount of glycosylated isoflavones (e.g., genistin) in North American soybeans is reported to be in the range of about 2.5 to 5 mg of glycosylated isoflavone/g dry soybean weight. Thus, a process of the present invention results in a production and recovery of genistein of about 25% of the genistein available. A typical industrial producer of erythromycin would use about 2,000 kg of crushed soybeans per tank (100,000 L) per week. This would potentially lead to the production of 5 kg of genistein per tank per week. A

30

35

medium scale producer of erythromycin could have 10 dedicated tanks for erythromycin production, and would therefore be capable of producing 50 kg of genistein per week.

5 Genistein was efficiently extracted from *Saccharopolyspora erythraea* fermentations at a pH of 9.5. This is significant because erythromycin is also extracted from *Saccharopolyspora erythraea* fermentations at this elevated pH (See, U.S. Patent 2,653,899, the disclosure of which is incorporated herein by reference). This means that in the industrial process genistein is co-purified with
10 erythromycin, at least through the first step. Genistein remains in the ethyl acetate fraction after the erythromycin is further purified by back extraction into acidified water. Genistein in the solvent fraction is effectively highly purified in the solvent distillate. Thus, not only are large quantities of genistein produced, but it is in a highly purified and concentrated state.

15 The present disclosure that genistein can be extracted from a bacterial fermentation medium at an alkaline pH in an organic solvent is surprising in view of the structure of genistein as well as reported methods of genistein isolation and recovery. As is well known, genistein, chemical name 4',6,7-
20 trihydroxyisoflavone, contains three hydroxyl groups. As is also well known, those hydroxyl groups tend to lose their hydrogen atoms and become negatively charged at alkaline pH values. As the pH increases, the solubility of genistein in an organic (non-polar) solvent would thus decrease and genistein should not be recoverable in that organic solvent. Indeed, all previous reports of genistein
25 isolation in organic solvents utilized an acidified environment (See, e.g., Chimura et al., *The Journal of Antibiotics*, 28:619, 1975; U.S. Patent Nos. 3,914,184 and 3,973,608; and Ogawara et al., *The Journal of Antibiotics*, 39:606, 1986).

WHAT IS CLAIMED IS:

1. A process of preparing genistein comprising fermenting *Saccharopolyspora erythraea* on a soy-based substrate.
2. The process of claim 1 further comprising recovering the genistein.
3. The process of claim 1 wherein *Saccharopolyspora erythraea* is cultured for a period of time and under culture conditions sufficient for genistein formation.
4. The process of claim 3 wherein *Saccharopolyspora erythraea* is cultured at a temperature of from about 10°C to about 45°C in an aqueous, oxygenated medium having a pH value of from about 4.0 to about 9.0, which medium contains organic nutrients, vitamins and inorganic salts sufficient to maintain *Saccharopolyspora erythraea* viability.
5. The process of claim 4 wherein the temperature is from about 20°C to about 30°C and the medium has a pH value of from about 6.0 to about 8.0.
6. The process of claim 3 wherein the period of time is from about 20 hours to about 250 hours.
7. The process of claim 2 wherein genistein is recovered by extracting genistein from a fermentation medium in a water-immiscible organic solvent at a pH value of from about 8.0 to about 11.0.
8. The process of claim 7 wherein the pH value is from about 9.0 to about 10.0.
9. The process of claim 7 wherein the organic solvent is ethyl acetate.

10. A process of recovering genistein from a bacterial fermentation medium comprising extracting genistein from the medium in an organic solvent at a pH value of from about 8.0 to about 11.0.

5 11. The process of claim 10 wherein the pH value is from about 9.0 to about 10.0.

12. The process of claim 10 wherein the organic solvent is ethyl acetate.

10 13. The process of claim 10 wherein the bacterial fermentation is a *Saccharopolyspora erythraea* fermentation.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/12563

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12P 17/06

US CL : 435/126, 252.1, 822

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/126, 252.1, 822

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,124,258 A (ARISON ET AL.) 23 June 1992, see Example 1.	1, 3-7
X	US 5,140,042 A (ARISON ET AL.) 18 August 1992, see Examples.	1, 3-7
X	US 5,141,926 A (WEBER ET AL.) 25 August 1992, see Examples.	1, 3-7
X	US 5,192,671 A (ARISON ET AL.) 09 March 1993, see Examples.	1, 3-7
A	US 4,366,248 A (ZILLIKEN) 28 December 1982, see entire document.	1-13

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A		document defining the general state of the art which is not considered to be of particular relevance
* E		earlier document published on or after the international filing date
* L		document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
* O		document referring to an oral disclosure, use, exhibition or other means
* P		document published prior to the international filing date but later than the priority date claimed
	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
	* &	document member of the same patent family

Date of the actual completion of the international search

29 OCTOBER 1996

Date of mailing of the international search report

13 NOV 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DR. HERBERT J. LILLING

Telephone No. (703) 308-0196